News >

Nivolumab Misses OS Endpoint in SCLC Study

Gina Columbus @ginacolumbusonc
Published: Friday, Oct 12, 2018

lung cancer
Single-agent nivolumab (Opdivo) did not improve overall survival (OS) compared with standard topotecan or amrubicin, where approved, in patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy, according to topline findings from the phase III CheckMate-331 trial.

Safety data were consistent with previously reported findings with single-agent nivolumab in patients with SCLC, according to Bristol-Myers Squibb (BMS), the developer of the PD-1 inhibitor.

“Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” Sabine Maier, MD, development lead, thoracic cancers for BMS, said in a press release. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. We thank the patients, their families, and the physicians involved in the CheckMate-331 study.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication